Key facts
- Neuvotion’s last known valuation is $6.5M (Jul 2021).
- It has raised $2.8M; the latest was Later Stage VC in Dec 2024.
- Notable investors include New York Angels, Accelerator for Biosciences in Connecticut, Forward Industries, Long Island Angel Network, Northwell Holdings — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Neuvotion
- ·The full record, as it builds
Funding rounds
No funding rounds for Neuvotion are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neuvotion
Developer of a healthcare technology designed to restore movement and independence for those living with movement impairment. The company combines targeted neurostimulation and AI to deliver therapeutic value for patients with a movement disorder or impairment from stroke or injury, enabling users to guide their own therapy and clinicians to leverage state-of-the-art technology while monitoring patient progress in-person or remotely.
- Sector
- Healthcare
- HQ
- Darien, CT, United States
- Founded
- 2019
- Employees
- 3
- Website
- neuvotion-inc.com/
- Ownership
- Privately Held (backing)
Neuvotion doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neuvotion shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neuvotion in its N-PORT filings yet. We sweep new filings monthly.